Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.1%) at 15,256 as of Monday, June 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,353 issues advancing vs. 1,578 declining with 107 unchanged. The Health Care sector currently sits up 0.6% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the sector include Catamaran ( CTRX), down 4.00, Regeneron Pharmaceuticals ( REGN), down 2.14, Smith & Nephew ( SNN), down 1.61, Celgene Corporation ( CELG), down 1.16 and Biogen Idec ( BIIB), down 1.25. Top gainers within the sector include ACADIA Pharmaceuticals ( ACAD), up 15.9%, UnitedHealth Group ( UNH), up 2.0%, Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.7%, Teva Pharmaceutical Industries ( TEVA), up 1.4% and Aetna ( AET), up 1.1%. TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today: 5. Dynavax Technologies Corporation ( DVAX) is one of the companies pushing the Health Care sector lower today. As of noon trading, Dynavax Technologies Corporation is down $0.88 (-35.4%) to $1.60 on heavy volume Thus far, 13.5 million shares of Dynavax Technologies Corporation exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $1.58-$1.84 after having opened the day at $1.82 as compared to the previous trading day's close of $2.47. Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Dynavax Technologies Corporation has a market cap of $466.4 million and is part of the drugs industry. Shares are down 10.5% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Dynavax Technologies Corporation a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Dynavax Technologies Corporation as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Dynavax Technologies Corporation Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.